0IV3 Stock Chart & Stats
$1.51
-$0.03(-1.71%)
At close: 4:00 PM EDT
$1.51
-$0.03(-1.71%)
Day’s Range― - ―
52-Week Range$1.04 - $2.00
Previous CloseN/A
Volume48.57K
Average Volume (3M)28.98K
Market Cap
$835.22M
Enterprise Value$807.52
Total Cash (Recent Filing)$300.85M
Total Debt (Recent Filing)$122.14M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Nov 11, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend Yield7.85%
Share Statistics
EPS (TTM)-0.10
Shares Outstanding642,473,400
10 Day Avg. Volume18,411
30 Day Avg. Volume28,983
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)3.90
Price to Sales (P/S)4.79
P/FCF Ratio-7.92
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.33Price Target Upside186.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$236.28M
Bulls Say, Bears Say
Bulls Say
RYTELO Revenue Growth And Account ExpansionStrong revenue growth alongside expanding prescribing accounts indicates increasing commercial adoption of RYTELO. Management’s expectation to reach the mid- to high-end of 2026 guidance supports continued product traction and a growing revenue base over the next several quarters.
Improving Operating LeverageExpenses declining while revenue grows demonstrates improving operating leverage and disciplined execution. If this relationship persists, Geron can convert commercial scale into narrower losses, preserve resources for clinical programs, and improve the durability of its business model.
Stronger Capital Structure And Cash PositionVery low leverage and substantial liquidity provide flexibility to fund commercialization and clinical development without the immediate burden of heavy debt service. This stronger capital structure improves resilience while Geron works toward sustainable profitability.
Bears Say
Persistent Cash Burn And UnprofitabilityDeeply negative operating and free cash flow show that the current business has not yet funded its operations internally. Continued losses can consume liquidity and increase reliance on external financing or balance-sheet resources, potentially limiting strategic flexibility.
Rising Gross-to-net DeductionsHigher gross-to-net deductions reduce realized revenue per unit and can weaken the economics of commercial growth even when prescription demand expands. Persistent pressure in the low- to mid-20% range would make the path to profitability more dependent on volume and cost control.
IMpactMF Interim-analysis UncertaintyUncertainty over the interim-analysis design adds complexity to the development and regulatory path for IMpactMF. Although the base-case final overall-survival timing remains targeted for H2 2028, changing parameters could affect readout expectations and execution planning.
Geron News
0IV3 FAQ
What was Geron Corp’s price range in the past 12 months?
Geron Corp lowest share price was $1.04 and its highest was $2.00 in the past 12 months.
What is Geron Corp’s market cap?
Geron Corp’s market cap is $835.22M.
When is Geron Corp’s upcoming earnings report date?
Geron Corp’s upcoming earnings report date is Nov 11, 2026 which is in 49 days.
How were Geron Corp’s earnings last quarter?
Geron Corp released its earnings results on Aug 05, 2026. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of -$0.009 by -$0.011.
Is Geron Corp overvalued?
According to Wall Street analysts Geron Corp’s price is currently Undervalued.
Does Geron Corp pay dividends?
Geron Corp pays a Notavailable dividend of $0.285 which represents an annual dividend yield of 7.85%. See more information on Geron Corp dividends here
What is Geron Corp’s EPS estimate?
Geron Corp’s EPS estimate is >-0.01.
How many shares outstanding does Geron Corp have?
Geron Corp has 642,473,400 shares outstanding.
What happened to Geron Corp’s price movement after its last earnings report?
Geron Corp reported an EPS of -$0.02 in its last earnings report, missing expectations of -$0.009. Following the earnings report the stock price went up 16.045%.
Which hedge fund is a major shareholder of Geron Corp?
Currently, no hedge funds are holding shares in GB:0IV3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Geron Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.33 (186.98% Upside)
$4.33 (186.98% Upside)
Blogger Sentiment
Bullish
GB:0IV3 Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.52%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Geron Corp
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
0IV3 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed positive commercial momentum and strengthening scientific evidence for RYTELO and the myelofibrosis program, supported by revenue growth (Q2 $57.5M, +17% YoY, +11% QoQ), expanding accounts and encouraging real-world data. The company also highlighted operational discipline (H1 operating expense down ~4% vs H1 revenue +24%) and a solid cash position ($327M). Counterbalancing these positives are rising gross-to-net deductions (20.7% in Q2 vs 15.3% prior year), a modest quarter-over-quarter cash decline, ongoing investment-driven spending, uncertainty around interim analysis modifications for IMpactMF, and unresolved EU pricing/MFN complexities that could affect ex-U.S. expansion. On balance the favorable revenue, evidence generation, and execution momentum outweigh the manageable risks and uncertainties.View all GB:0IV3 earnings summaries0IV3 Stock 12 Month Forecast
Average Price Target
$4.33
▲(186.98% Upside)